CoChat
Sign Up
Cited by 103

The DOI matches its Crossref record.

Drug-Induced Liver Injury: Highlights of the Recent Literature

Real, Mark, Barnhill, Michele S., Higley, Cory, Rosenberg, Jessica, Lewis, James H.·2019·Drug Safety
DOI 10.1007/s40264-018-0743-2
Open this paper in CoChat — free account

Abstract

Drug-induced liver injury (DILI), herbal-induced liver injury, and herbal and dietary supplement (HDS)-induced liver injury are an important aspect of drug safety. Knowledge regarding responsible drugs, mechanisms, risk factors, and the diagnostic tools to detect liver injury have continued to grow in the past year. This review highlights what we considered the most significant publications from among more than 1800 articles relating to liver injury from medications, herbal products, and dietary supplements in 2017 and 2018. The US Drug-Induced Liver Injury Network (DILIN) prospective study highlighted several areas of ongoing study, including the potential utility of human leukocyte antigens and microRNAs as DILI risk factors and new data on racial differences, the role of alcohol consumption, factors associated with prognosis, and updates on the clinical signatures of autoimmune DILI, thiopurines, and HDS agents. Novel data were also generated from the Spanish and Latin American DILI registries as well as from Chinese and Korean case series. A few new agents causing DILI were added to the growing list in the past 2 years, including sodium-glucose co-transporter-2 inhibitors, as were new aspects of chemotherapy-associated liver injury. A number of cases reported previously described hepatotoxins confirmed via the Roussel Uclaf Causality Assessment Method (RUCAM; e.g., norethisterone, methylprednisolone, glatiramer acetate) and/or the DILIN method (e.g., celecoxib, dimethyl f…

Overview

Integrity signals

Registry

Crossref · 10.1007/s40264-018-0743-2

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 165

  1. de Boer YS, Kosinski AS, Urban TJ, Zhao Z, Long N, Chalasani N, et al. Features of autoimmune hepatitis in patients with drug-induced liver injury. Clin Gastroenterol Hepatol. 2017;15(1):103–12. · DOI · Paper page
  2. Nicoletti P, Aithal GP, Bjornsson ES, Andrade R, Sawle A, Arrese M, International Drug-Induced Liver Injury Consortium, Drug-Induced Liver Injury Network Investigators, and International Serious Adverse Events Consortium, et al. Association of liver injury from specific drugs, or groups of drugs, with polymorphisms in HLA and other genes in a genome-wide association study. Gastroenterology. 2017;152(5):1078–89. · DOI · Paper page
  3. Urban TJ, Nicoletti P, Chalasani N, Serrano J, Stolz A, Daly A, et al. Minocycline hepatotoxicity: clinical characterization and identification of HLA-B*35:02 as a risk factor. J Hepatol. 2017;67(1):137–44. · DOI · Paper page
  4. Whritenour J, Ko M, Zong Q, Wang J, Tartaro K, Schneider P, et al. Development of a modified lymphocyte transformation test for diagnosing drug-induced liver injury associated with an adaptive immune response. J Immunotoxicol. 2017;14(1):31–8. · DOI · Paper page
  5. Russo MW, Steuerwald N, Norton HJ, Anderson WE, Foureau D, Chalasani N, et al. Profiles of miRNAs in serum in severe acute drug induced liver injury and their prognostic significance. Liver Int. 2017;37(5):757–64. · DOI
  6. Bonkovsky HL, Kleiner DE, Gu J, Odin JA, Russo MW, Navarro VM, et al. Clinical presentations and outcomes of bile duct loss caused by drugs and herbals and dietary supplements. Hepatology. 2017;65(4):1267–77. · DOI · Paper page
  7. Navarro VJ, Khan I, Björnsson E, Seeff LB, Serrano J, Hoofnagle JH. Liver injury from herbal and dietary supplements. Hepatology. 2017;65(1):363–73. · DOI
  8. Vega M, Verma M, Beswick D, Bey S, Hossack J, Merriman N, et al. The incidence of drug- and herbal and dietary supplement-induced liver injury: preliminary findings from gastroenterologist-based surveillance in the population of the state of Delaware. Drug Saf. 2017;40(9):783–7. · DOI · Paper page
  9. Suzuki A, Barnhart H, Gu J, Bonkovsky HL, Tillmann HL, Fontana RJ, et al. Associations of gender and a proxy of female menopausal status with histological features of drug-induced liver injury. Liver Int. 2017;37:1723–30. · DOI
  10. Chalasani N, Reddy KR, Fontana RJ, Barnhart H, Gu J, Hayashi PH, et al. Idiosyncratic drug induced liver injury in african-americans is associated with greater morbidity and mortality compared to Caucasians. Am J Gastroenterol. 2017;112(9):1382–8. · DOI · Paper page
  11. Hayashi PH, Rockey DC, Fontana RJ, Tillmann HL, Kaplowitz N, Barnhart HX, et al. Death and liver transplantation within 2 years of onset of drug-induced liver injury. Hepatology. 2017;66(4):1275–85. · DOI · Paper page
  12. Dakhoul L, Ghabril M, Gu J, Navarro V, Chalasani N, Serrano J, United States Drug Induced Liver Injury Network. Heavy consumption of alcohol is not associated with worse outcomes in patients with idiosyncratic drug-induced liver injury compared to non-drinkers. Clin Gastroenterol Hepatol. 2018;16(5):722–9. · DOI · Paper page
  13. Ahmad J, Rossi S, Rodgers SK, Ghabril M, Fontana RJ, Stolz A, et al. Sclerosing cholangitis-like changes on magnetic resonance cholangiography in patients with drug induced liver injury. Clin Gastroenterol Hepatol. 2018. https://doi.org/10.1016/j.cgh.2018.06.035 . · DOI
  14. Fontana RJ, et al. The role of HLA-A*33:01 in patients with cholestatic hepatitis attributed to terbinafine. J Hepatol. 2018. https://doi.org/10.1016/j.jhep.2018.08.004 . · DOI
  15. Zoubek ME, González-Jimenez A, Medina-Cáliz I, Robles-Díaz M, Hernandez N, Romero-Gómez M, et al. High prevalence of ibuprofen drug-induced liver injury in Spanish and Latin-American Registries. Clin Gastroenterol Hepatol. 2018;16(2):292–4. · DOI
  16. Medina-Caliz I, Garcia-Cortes M, Gonzalez-Jimenez A, Cabello MR, Robles-Diaz M, Sanabria-Cabrera J, Spanish DILI Registry, et al. Herbal and dietary supplement-induced liver injuries in the Spanish DILI Registry. Clin Gastroenterol Hepatol. 2018;16(9):1495–502. · DOI · Paper page
  17. Bjornsson E, Jiezhun G, Kleiner D, Chalasani N, Hayashi P, Hoofnagle J. Azathioprine and 6-mercaptopurine-induced liver injury: clinical features and outcomes. J Clin Gastroenterol. 2017;51(1):63–9. · DOI
  18. Björnsson ES, Bergmann O, Jonasson JG, Grondal G, Gudbjornsson B, Olafsson S. Drug-induced autoimmune hepatitis: response to corticosteroids and lack of relapse after cessation of steroids. Clin Gastroenterol Hepatol. 2017;15(10):1635–6. · DOI · Paper page
  19. Yu YC, Mao YM, Chen CW, Chen JJ, Chen J, Cong WM, et al. CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hepatol Int. 2017;11(3):221–41. · DOI · Paper page
  20. Cho JH, Oh DS, Hong SH, Ko H, Lee NH, Park SE, et al. A nationwide study of the incidence rate of herb-induced liver injury in Korea. Arch Toxicol. 2017;91(12):4009–15. · DOI · Paper page
  21. Melchart D, Hager S, Albrecht S, Dai J, Weidenhammer W, Teschke R. Herbal traditional Chinese medicine and suspected liver injury: a prospective study. World J Hepatol. 2017;9(29):1141–57. · DOI · Paper page
  22. Dalal KK, Holdbrook T, Peikin SR. Ayurvedic drug induced liver injury. World J Hepatol. 2017;9(31):1205–9. · DOI · Paper page
  23. Shaikh SA, Tischer S, Choi EK, Fontana RJ. Good for the lung but bad for the liver? Garlic-induced hepatotoxicity following liver transplantation. J Clin Pharm Ther. 2017;42(5):646–8. · DOI
  24. Xiao A, He HY, Chen Q, Ma SW. Drug-induced liver injury due to Lepidium meyenii (Maca) medicinal liquor. Chin Med J (Engl). 2017;130(24):3005–6. · DOI
  25. Li H, Wang X, Liu Y, Pan D, Wang Y, Yang N, et al. Hepatoprotection and hepatotoxicity of Heshouwu, a Chinese medicinal herb: context of the paradoxical effect. Food Chem Toxicol. 2017;108(Pt B):407–18. · DOI
  26. Tayabali K, Bolzon C, Foster P, Patel J, Kalim MO. Kratom: a dangerous player in the opioid crisis. J Community Hosp Intern Med Perspect. 2018;8(3):107–10. · DOI
  27. Fluyau D, Revadigar N. Biochemical benefits, diagnosis and clinical risks evaluation of Kratom. Front Psychiatry. 2017;8:62. · DOI
  28. Chang-Chien G, Odonkor C, Amorapanth P. Is kratom the new ‘legal high’ on the block? The case of an emerging opioid receptor agonist with substance abuse potential. Pain Physician. 2017;20(1):E195–8. · DOI
  29. Kothadia J, Kaminski M, Samant H, Olivera-Martinez M. Hepatotoxicity associated with use of the weight loss supplement Garcinia cambogia: a case report and review of the literature. Case Rep Hepatol. 2018;2018:6483605.
  30. Sharma A, Akagi E, Njie A, Goyal S, Arsene C, Krishnamoorthy G, et al. Acute hepatitis due to Garcinia cambogia extract, an herbal weight loss supplement. Case Rep Gastrointest Med. 2018;2018:6360543.
  31. Corey R, Werner K, Singer A, Moss A, Smith M, Noelting J, et al. Acute liver failure associated with Garcinia cambogia use. Ann Heptaol. 2016;15(1):123–6. · DOI
  32. Lunsford K, Bodzin A, Reino D, Wang HL, Busuttil RW. Dangerous dietary supplements: Garcinia cambogia-associated hepatic failure requiring transplantation. World J Gastroenterol. 2016;22(45):10071–6. · DOI
  33. Cescioli G, Lombardi N, Bettiol A, Marconi E, Risaliti F, Bertoni M, et al. Acute liver injury following Garcinia cambogia weight-loss supplementation: case series and literature review. Intern Emerg Med. 2018;13(6):857–72. · DOI
  34. Phillips CA, Paramaguru R, Joy AK, Antony KL, Augustine P. Clinical outcomes, histopathological patterns, and chemical analysis of Ayurveda and herbal medicine associated with severe liver injury—a single center experience from southern india. Indian J Gastroenterol. 2018;37(1):9–17. · DOI · Paper page
  35. Devarbhavi H. Ayurvedic and herbal medicine-induced liver injury: it is time to wake up and take notice. Indian J Gastroenterol. 2018;37(1):5–7. · DOI
  36. Wang Y, Wang L, Saxena R, Wee A, Yang R, Tian Q, et al. Clinicopathological features of He Shou Wu-induced liver injury: this ancient anti-aging therapy is not liver-friendly. Liver Int. 2018. https://doi.org/10.1111/liv.13939 . · DOI
  37. Mazzanti G, Moro P, Raschi E, Da Cas R, Menniti-Ippolito F. Adverse reactions to dietary supplements containing red yeast rice: assessment of cases from the Italian surveillance system. Br J Clin Pharmacol. 2017;83:894–908. · DOI · Paper page
  38. Teschke R, Schulze J, Eickhoff A. Drug induced liver injury: can biomarkers assist RUCAM in causality assessment? Int J Mol Sci. 2017;18:803. · DOI
  39. Robles-Díaz M, Medina-Caliz I, Stephens C, Andrade RJ, Lucena MI. Biomarkers in DILI: one more step forward. Front Pharmacol. 2016;7:267. · DOI
  40. Lin H, Ewing LE, Koturbash I, Gurley BJ, Miousse IR. MicroRNAs as biomarkers for liver injury: current knowledge, challenges and future prospects. Food Chem Toxicol. 2017;110:229–39. · DOI
  41. Church RJ, Watkins PB. The transformation in biomarker detection and management of drug-induced liver injury. Liver Int. 2017;37(11):1582–90. · DOI
  42. Mosedale M, Watkins P. Drug-induced liver injury: advances in mechanistic understanding that will inform risk management. Clin Pharmacol Ther. 2017;101(4):469–80. · DOI
  43. Kullak-Ublick GA, Andrade RJ, Merz M, End P, Benesic A, Gerbes AL, et al. Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut. 2017;66:1154–64. · DOI · Paper page
  44. Araújo AM, Carvalho M, Carvalho F, Bastos ML, Gueses de Pinho P. Metabolomic approaches in the discovery of potential urinary biomarkers of drug-induced liver injury (DILI). Crit Rev Toxicol. 2017;47(8):633–49. · DOI
  45. Gonzalez-Jimenez A, McEuen K, Chen M, Suzuki A, Robles-Diaz M, Medina-Caliz I, et al. The influence of drug properties and host factors on delayed onset of symptoms in drug-induced liver injury. Liver Int. 2018. https://doi.org/10.1111/liv.13952 . · DOI
  46. Fang WC, Adler NR, Graudins LV, Goldblatt C, Goh MS, Roberts SK, et al. Drug-induced liver injury is frequently associated with severe cutaneous adverse drug reactions: experience from two Australian tertiary hospitals. Intern Med J. 2018;48(5):549–55. · DOI
  47. McGill MR, Jaeschke H. Biomarkers of drug-induced liver injury: progress and utility in research, medicine and regulation. Expert Rev Mol Diagn. 2018;18(9):797–807. · DOI
  48. Osanlou O, Pirmohamed M, Daly AK. Pharmacogenetics of adverse drug reactions. Adv Pharmacol. 2018;83:155–90. · DOI
  49. Kaliyaperumal K, Grove JI, Delahay RM, Giffiths WJ, Duckworth A, Aithal GP. Pharmacogenomics of drug-induced liver injury (DILI): molecular biology to clinical applications. J Hepatol. 2018. https://doi.org/10.1016/j.jhep.2018.05.013 . · DOI
  50. Bessone F, Dirchwolf M, Rodil MA, Razori MV, Roma MG. Review article: drug-induced liver injury in the context of nonalcoholic fatty liver disease—a physiopathological and clinical integrated view. Aliment Pharmacol Ther. 2018;1:1. https://doi.org/10.1111/apt.14952 . · DOI
  51. Kowalec K, Wright GE, Drogemoller BI, Aminkeng F, Bhavsar AP, Kingwell E, et al. Common variation near IRF6 is associated with IFN-beta-induced liver injury in multiple sclerosis. Nat Genet. 2018;50(8):1081–5. · DOI
  52. Marcinak JF, Munsaka MS, Watkins PB, Ohira T, Smith N. Liver safety of fasiglifam (TAK-875) in patients with type 2 diabetes: review of the global clinical trial experience. Drug Saf. 2018;41(6):625–40. · DOI
  53. The Lancet. End of the road for daclizumab in multiple sclerosis. Lancet. 2018;391(10125):1000. https://doi.org/10.1016/s0140-6736(18)30565-8 . · DOI
  54. Buege MJ, Brown JE, Aitken SL. Solithromycin: a novel ketolide antibiotic. Am J Health Syst Pharm. 2017;74(12):875–87. · DOI
  55. Roth F, Maiuri A, Ganey P. Idiosyncratic drug-induced liver injury: is drug-cytokine interaction the linchpin? J Pharmacol Exp Ther. 2017;360(2):461–70. · DOI
  56. Jian J, Mathijs K, Timmermans L. Omics-based identification of the combined effects of idiosyncratic drugs and inflammatory cytokines on the development of drug-induced liver injury. Toxicol Appl Pharmacol. 2017;332:100–8. · DOI
  57. Kato R, Uetrecht J. Supernatant from hepatocyte cultures with drugs that cause idiosynratic liver injury activates macrophage inflammasomes. Chem Res Toxicol. 2017;30(6):1327–32. · DOI
  58. Hu J, Ramshesh V, McGill M, Jaeschke H, Lemasters JJ. Low dose acetaminophen induces reversible mitochondrial dysfunction associated with transient c-Jun N-terminal kinase activation in mouse liver. Toxicol Sci. 2016;150(1):204–15. · DOI
  59. Ramachandran A, Jaeschke H. Acetaminophen toxicity novel insights into mechanisms and future perspectives. Gene Expr. 2018;18(1):19–30. · DOI
  60. Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy. 2004;59(8):809–20. · DOI · Paper page
  61. Saito M, Yagi M, Uno K, Takanaka K. Comparative study of the usefulness of the drug-induced lymphocyte stimulation test and the leukocyte migration test in drug allergies. Biol Pharm Bull. 2008;31(2):299–304. · DOI
  62. Benesic A, Rotter I, Dragoi D, Weber S, Buchholtz ML, Gerbes AL. Development and validation of a test to identify drugs that cause idiosyncratic drug-induced liver injury. Clin Gastroenterol Hepatol. 2018;16(9):1488–94. · DOI · Paper page
  63. Bessone F. Predicting fatalities in serious idiosyncratic drug-induced liver injury—a matter of choosing the best Hy’s law. Transl Gastroenterol Hepatol. 2017;2:112. · DOI
  64. Bjornsson ES, Bjornsson HK. Mortality associated with drug-induced liver injury (DILI). Transl Gastroenterol Hepatol. 2017;2:114. · DOI
  65. Chalasani NP, Hayashi PH, Bonkovsky HL, Navarro VJ, Lee WM, Fontana RJ, Practice Parameters Committee of the American College of Gastroenterology. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014;109(7):950–66. · DOI · Paper page
  66. Teschke R, Danan G. Drug induced liver injury with analysis of alternative causes as confounding variables. Br J Clin Pharmacol. 2018;84(7):1467–77. · DOI
  67. Malnick S, Maor Y, Melzer E, Ziv-Sokolowskaia NN, Nueman MG. Severe hepatotoxicity linked to Denosumab. Eur Rev Med Pharmacol Sci. 2017;21(1 Suppl):78–85.
  68. Namn Y, Scneider Y, Cui I, Jesudian A. Diphenhydramine as a cause of drug-induced liver injury. Case Reports Hepatol. 2017;2017:3864236. · DOI
  69. Niijima K, Niijimia Y, Okada S. Drug-induced liver injury cause by ipragliflozin administration with causality established by a positive lymphocyte transformation test (LTT) and the RUCAM: a case report. Ann Hepatol. 2017;16(2):308–11. · DOI
  70. Ito D, Shimizu S, Inoue K, Saito D, Yanagisawa M, Inukai K, et al. Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-week, open-label, active-controlled trial. Diabetes Care. 2017;40(10):1364–72. · DOI
  71. Patel S, Mendler MH, Valasek MA, Tsunoda SM. Drug-induced liver injury associated with the use of everolimus in a liver transplant patient. Case Rep Transpl. 2018;2018:7410508.
  72. Park DH, Yun GY, Eun HS, Joo JS, Kim JS, Kang SH, et al. Fimasartan-induced liver injury in a patient with no adverse reactions on other types of angiotensin II receptor blockers: a case report. Medicine (Baltimore). 2017;96(47):e8905. · DOI
  73. Aschenbrenner DS. Excessive dosing of obeticholic acid may increase risk of liver damage. Am J Nurs. 2018;118(2):46.
  74. Lugoboni F, Mirijello A, Morbioli L, Arzenton E, Leone R, Faccini M, et al. Does high-dose benzodiazepine abuse really produce liver toxicity? Results from a series of 201 benzodiazepine mono-abusers. Expert Opin Drug Saf. 2018;17(5):451–6. · DOI
  75. Honda S, Sawada K, Hasebe T, Nakajima S, Fujiya M, Okumura T. Tegafur-uracil-induced rapid development of advanced hepatic fibrosis. World J Gastroenterol. 2017;23(31):5823–8. · DOI
  76. Edwards B, Raisch D, Saraykar S, Sun M, Hammel J, Tran H, et al. Hepatotoxicity with vismodegib: an MD Anderson cancer center and research on adverse drug events and reports project. Drugs RD. 2017;17(1):211–8. · DOI
  77. Sakumura M, Tajiri K, Miwa S, Nagata K, Kawai K, Miyazono T, et al. Hepatic sinusoidal obstruction syndrome induced by non-transplant chemotherapy for non-Hodgkin lymphoma. Intern Med. 2017;56(4):395–400. · DOI
  78. Shah JM, Lin K, Etienne D, Reddy M, Liu Y. Imatinib-induced hepatitis in a patient treated for gastrointestinal stromal tumor: a rare adverse effect. Cureus. 2018;10(4):e2529.
  79. McDonald GB, Freston JW, Boyer JL, DeLeve LD. Liver complications following treatment of hematologic malignancy with anti-cd22-calicheamicin (inotuzumab ozogamicin). Hepatology. 2018;1:1. https://doi.org/10.1002/hep.30222 . · DOI
  80. Tanaka R, Fujisawa Y, Sae I, Maruyama H, Ito S, Hasegawa N, et al. Severe hepatitis arising from ipilimumab administration, following melanoma treatment with nivolumab. Jpn J Clin Oncol. 2017;47(2):175–8. · DOI
  81. Eigentler TK, Hassel JC, Verking C, Aberle J, Bachmann O, Grunwald V, et al. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev. 2016;45:7–18. · DOI
  82. Gelsomino F, Vitale G, D’Errico A, Bertuzzi C, Andreone P, Ardizzoni A. Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury. Ann Oncol. 2017;28(3):671–2. · DOI
  83. Matsubara T, Nishida T, Higaki Y, Tomita R, Shimakoshi H, Shimoda A, Osugi N, Sugimoto A, Takahashi K, Nakamatsu D, Mukai K, Yamamoto M, Fukui K, Adachi S, Inada M. Nivolumab induces sustained liver injury in a patient with malignant melanoma. Intern Med. 2018;57(12):1789–92. · DOI
  84. Abdel-Rahman O, ElHalawani H, Fouad M. Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Expert Opin Drug Saf. 2015;14:1507–18. · DOI
  85. Zarrabi K, Wu S. Risk of liver toxicity with nivolumab immunotherapy in cancer patients. Oncology. 2018;94:259–73. · DOI
  86. Zen Y, Yeh MM. Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury. Mod Pathol. 2018;31:965–73. · DOI · Paper page
  87. Vigano L, De Rosa G, Toso C, Andres A, Ferrero A, Roth A, et al. Reversibility of chemotherapy-related liver injury. J Hepatol. 2017;67(1):84–91. · DOI
  88. Wakiya T, Kudo D, Ishido K, Kimura N, Yakoshi Y, Toyoki Y, et al. Effect of age on the development of chemotherapy-associated liver injury in colorectal cancer liver metastasis. Mol Clin Oncol. 2017;7(2):200–4.
  89. Zhanel GG, Hartel E, Adam H, Zelenitsky S, Zhanel MA, Golden A, et al. Solithromycin: a novel fluoroketolide for the treatment of community-acquired bacterial pneumonia. Drugs. 2016;76(18):1737–57. · DOI
  90. Donald BJ, Surani S, Deol HS, Mbadugha UJ, Udeani G. Spotlight on solithromycin in the treatment of community-acquired bacterial pneumonia: design, development, and potential place in therapy. Drug Des Dev Ther. 2017;11:3559–66. · DOI
  91. Dobbins R, Gholam P, Ertel S, Furey N, Baskaran GM, Goodman Z, Oldach D, Fernandes P. SAT-299—solithromycin treatment for 13 weeks improves histological parameters in nonalcoholic steatohepatitis: results of an ongoing pilot study. J. Hepatol. 2017;66(1):S586. · DOI
  92. Wong A, Sivilotti M, Graudins A. Accuracy of the paracetamol-aminotransferase multiplication product to predict hepatotoxicity in modified-release paracetamol overdose. Clin Toxicol (Phila). 2017;55(5):346–51. · DOI
  93. Sivilotti MLA, Green TJ, Langmann C, Yarema M, Juurlink D, Johnson D. Multiplying the serum aminotransferase by the acetaminophen concentration to predict toxicity following overdose. Clin Toxicol. 2010;48:793–9. · DOI · Paper page
  94. Chomchai S, Chomchai C. Predicting acute acetaminophen hepatotoxicity with acetaminophen-aminotransferase multiplication product and the Psi parameter. Clin Toxicol. 2014;52:506–11. · DOI
  95. Heard K, Anderson V, Dart R. Serum acetaminophen protein adduct concentrations in pediatric emergency department patients. Hepatology. 2017;64(4):533–5.
  96. Heard K, Anderson V, Lavonas E. Serum paracetamol-protein adducts in ambulatory subjects: relationship to recent reported paracetamol use. Biomarkers. 2018;23(3):288–92. · DOI
  97. Heruth DP, Shortt K, Zhang N, Li DY, Zhang LQ, Ye SQ. Genetic association of single nucleotide polymorphisms with acetaminophen-induced hepatotoxicity. J Pharmacol Exp Ther. 2018. https://doi.org/10.1124/jpet.118.248583 . · DOI
  98. Roberts D, Lee W, Hinson J, Bai S, Swearingen CJ, Stravitz RT, et al. An immunoassay to rapidly measure acetaminophen protein adducts accurately identifies patients with acute liver injury or failure. Clin Gastroenterol Hepatol. 2017;15(4):555–62. · DOI
  99. Dob S, Potschka H, Dob F, Mitzner S, Sauer M. Hepatotoxicity of antimycotics used for invasive fungal infections: in vitro results. Biomed Res Int. 2017;2017:9658018.
  100. Pettit NN, Miceli MH, Rivera CG, Naraynanan PP, Perissinotti AJ, Hsu M, et al. Multicentre study of posaconazole delayed-release tablet serum level and association with hepatotoxicity and QTc prolongation. J Antimicrob Chemother. 2017;72(8):2355–8. · DOI
  101. Gayam V, Khalid M, Dahal S, Garlapati P, Gill A. Hyperacute liver injury following intravenous fluconazole: a rare case of dose-independent hepatotoxicity. J Family Med Prim Care. 2018;7(2):451–4. · DOI
  102. Watkins PB, Lewis JH, Kaplowitz N, Alpers DH, Blais JD, Smotzer DM, et al. Clinical pattern of tolvaptan-associated liver in- jury in subjects with autosomal dominant polycystic kidney disease: analysis of clinical trials database. Drug Saf. 2015;38:1103–13. · DOI
  103. Oi A, Morishita K, Awogi T, Ozaki A, Umezato M, Fujita S, et al. Nonclinical safety profile of tolvaptan. Cardiovasc Drugs Ther. 2011;1:S91–9. · DOI
  104. Mosedale M, Kim Y, Brock W, Roth SE, Wiltshire T, Eaddy JS, et al. Editor’s highlight: candidate risk factors and mechanisms for tolvaptan-induced liver injury are identified using a collaborative cross approach. Toxicol Sci. 2017;156(2):438–54.
  105. Festing MFW. Inbred strains should replace outbred stocks in toxicology, safety testing, and drug development. Toxicol Pathol. 2010;38(5):681–90. · DOI
  106. Harrill AH, DeSmet KD, Wolf KK, Bridges AS, Eaddy JS, Kurtz CL, et al. A mouse diversity panel approach reveals the potential for clinical kidney injury due to DB289 not predicted by classical rodent models. Toxicol Sci. 2012;130(2):416–26. · DOI
  107. Mosedale M, Eaddy JS, Trask OJ, Holman NS, Wolf KK, LeCluyse E, et al. miR-122 release in exosomes precedes overt tolvaptan-induced necrosis in a primary human hepatocyte micropatterned coculture model. Toxicol Sci. 2018;161(1):149–58. · DOI
  108. Woodhead JF, Watkins PB, Howell BA, Siler SQ, Shoda LK. The role of quantitative systems pharmacology modeling in the prediction and explanation of idiosyncratic drug-induced liver injury. Drug Metab Pharmacokinet. 2017;32(1):40–5. · DOI
  109. Woodhead JF, Brock WJ, Roth SE, Shoaf SE, Brouwer KL, Church R, et al. Application of a mechanistic model to evaluate putative mechanisms of tolvaptan drug-induced liver injury and identify patient susceptibility factors. Toxicol Sci. 2017;155(1):61–74. · DOI
  110. Barnhill M, Real M, Lewis J. Latest advances in diagnosing and predicting DILI: what was new in 2017. Expert Rev Gastroenterol Hepatol. 2018. https://doi.org/10.1080/17474124.2018.1512854 . · DOI
  111. Suzuki A, Andrade RJ, Bjornsson E, Lucena MI, Lee WM, Yuen NA, et al. Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work. Drug Saf. 2010;33:503–22. · DOI
  112. Bjornsson ES, Hoofnagle JH. Categorization of drugs implicated in causing liver injury: critical assessment based on published case reports. Hepatology. 2016;63:590–603. · DOI · Paper page
  113. Shirai Y, Oda S, Makino S. Establishment of a mouse model of enalapril-induced liver injury and investigation of the pathogenesis. Lab Investig. 2017;97(7):833–42. · DOI
  114. Liakoni E, Ratz Bravo AE, Krahenbuhl S. Hepatotoxicity of new oral anticoagulants (NOACs). Drug Saf. 2015;38:711–20. · DOI
  115. Glenn K, Chen P, Musleh M. A rare case of rivaroxaban causing delayed symptomatic hepatocellular injury and hyperbilirubinemia. Case Rep Gastrointest Med. 2017;2017:5678187.
  116. Alonso A, MacLehose R, Chen L, Bengtson L, Chanberlain A, Norby F, et al. Prospective study of oral anticoagulants and risk of liver injury in atrial fibrillation patients. Heart. 2017;103(11):834–939. · DOI
  117. Douros A, Azoulay L, Yin H, Suissa S, Renoux C. Non-vitamin K antagonist oral anticoagulants and risk of serious liver injury. JACC. 2018;71(10):1105–13. · DOI
  118. Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, et al. Updated European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with nonvalvular atrial fibrillation. Europace. 2015;17:1467–507. · DOI
  119. Sarges P, Steinberg JM, Lewis JH. Drug-induced liver injury: highlights from a review of the 2015 literature. Drug Saf. 2016;2016:1–21.
  120. Mishra P, Chen M. Direct-Acting antivirals for chronic hepatitis C: can drug properties signal potential for liver injury? Gastroenterol. 2017;152(6):1270–4. · DOI
  121. Chen M, Borlak J, Tong W. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug induced liver injury. Hepatology. 2013;58:388–96. · DOI · Paper page
  122. Segamwenge IL, Bernard MK. Acute liver failure among patients on efavirenz-based antiretroviral therapy. Case Rep Hepatol. 2018. https://doi.org/10.1155/2018/1270716 . · DOI
  123. Diab OA, Kamel J, Abd-Elhamid AA. Predictors of intravenous amiodarone induced liver injury. Egypt Heart J. 2017;69(1):45–54. · DOI
  124. Grimaldi-Bensouda L, Matthias A, et al. Dronedarone, amiodarone and other antiarrhythmic drugs, and acute liver injuries: a case-referent study. Int J Cardiol. 2018;266:100–5. · DOI
  125. Suvichapanich S, Fukunaga K, Zahroh H, Mushiroda T, Mahasirimongkol S, Toyo-oka L, et al. NAT2: ultra-slow acetylator and risk of anti-tuberculosis drug-induced liver injury: a genotype-based meta-analysis. Pharmacogenet Genom. 2018;28(7):167–76. · DOI
  126. Zhang M, Wang S, Wilffert B, Tong R, van Soolingen D, van den Hof S, Alffenaar JW. The association between the NAT2 genetic polymorphisms and risk of DILI during anti-TB treatment: a systematic review and meta-analysis. Br J Clin Pharmacol. 2018. https://doi.org/10.1111/bcp.13722 . · DOI
  127. Nociti V, Biolato M, De Fino C, Bianco A, Losavio FA, Lucchini M, et al. Liver injury after pulsed methylprednisolone therapy in multiple sclerosis patients. Brain Behav. 2018;8(6):e00968. https://doi.org/10.1002/brb3.968 . · DOI
  128. Bresteau C, Prevot S, Perlemuter G, Voican C. Methylprednisolone-induced acute liver injury in a patient treated for multiple sclerosis relapse. BMJ Case Rep. 2018. https://doi.org/10.1136/bcr-2017-223670 . · DOI
  129. Dumortier J, Cottin J, Lavie C. Methylprednisolone liver toxicity: A new case and a French regional pharmacovigilance survey. Clin Res Hepatol Gastroenterol. 2017;41(4):497–501. · DOI
  130. Billioti de Gage S, Collin C, Le-Tri T, Pariente A, Bégaud B, Verdoux H, Dray-Spira R, Zureik M. Antidepressants and hepatotoxicity: a cohort study among 5 million individuals registered in the French National Health Insurance Database. CNS Drugs. 2018;32(7):673–84. · DOI
  131. Ferrajolo C, Scavone C, Donati M, Bortolami O, Stoppa G, Motola D, DILI-IT Study Group, et al. Antidepressant-induced acute liver injury: a case–control study in an Italian Inpatient Population. Drug Saf. 2017;41(1):95–102. · DOI
  132. Kok B, Lester EL, Lee WM, Hanje AJ, Stravitz RT, Girgis S, United States Acute Liver Failure Study Group, et al. Acute liver failure from tumor necrosis factor-α antagonists: report of four cases and literature review. Dig Dis Sci. 2018;63(6):1654–66. · DOI
  133. Barnhill M, Lewis JH. Are authors following the rules for causality assessment? Gastroenterology. 2018;154(6):S-1227 (abstract #2910244). · DOI
  134. Wong MC, Huang JL, George J, Huang J, Leung C, Eslam M, et al. The changing epidemiology of liver diseases in the Asia-Pacific region. Nat Rev Gastroenterol Hepatol. 2018. https://doi.org/10.1038/s41575-018-0055.0 . · DOI
  135. Wang R, Qi X, Yoshida EM, Mendez-Sanchez N, Teschke R, Sun M, et al. Clinical characteristics and outcomes of traditional Chinese medicine-induced liver injury: a systematic review. Expert Rev Gastroenterol Hepatol. 2018;12(4):425–34. · DOI · Paper page
  136. Liu Z, He X, Wang L, Zhang Y, Hai Y, Gao R. Chinese herbal medicine hepatotoxicity: the evaluation and recognization based on large-scale evidence database. Curr Drug Metab. 2018. https://doi.org/10.2174/1389200219666180813144114 . · DOI
  137. Wang JB, Zhu Y, Bai ZF, Wang FS, Li XH, Xiao XH, et al. Guidelines for the diagnosis and management of herb-induced liver injury. Chin J Integr Med. 2018;24(9):696–706. · DOI · Paper page
  138. Jing J, Teschke R. Traditional Chinese medicine and herb-induced liver injury: comparison with drug-induced liver injury. J Clin Transl Hepatol. 2018;6(1):57–68. · DOI
  139. Danan G, Teschke R. Review: RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci. 2016;17(14):1–33.
  140. Agarwal VK, McHutchinson JG, Hoofnagle JH. Important elements for the diagnosis of drug-induced liver injury. Clin Gastroenterol Hepatol. 2010;8(5):463–70. · DOI
  141. Ganger DR, Rule J, Rakela J, Bass N, Reuben A, Stravitz RT, et al. Acute liver failure of indeterminate etiology: a comprehensive systematic approach by an expert committee to establish causality. Am J Gastroenterol. 2018. https://doi.org/10.1038/s41395-018-0160-2 . · DOI
  142. Scalfaro E, Streefkerk H, Merz M, Meier C, Lewis D. Preliminary results of a novel algorithmic method aiming to support initial causality assessment of routine pharmacovigilance case reports for medication-induced liver injury: the PV-RUCAM. Drug Saf. 2017;40(8):715–27. · DOI · Paper page
  143. Lauschke V. Dysregulation of miR-223 constitutes a promising biomarker that informs about clinical outcomes of acute liver failure. Clin Sci (Lond). 2017;131(15):2059–62. · DOI
  144. Fang C, Li XP, Gong WJ, Wu NY, Tang J, Yin JY, et al. Age-related common miRNA polymorphism associated with severe toxicity in lung cancer patients treated with platinum-based chemotherapy. Clin Exp Pharmacol Physiol. 2017;44(Suppl 1):21–9. · DOI
  145. Yang R, Yang F, Huang Z, Jin Y, Sheng Y, Ji L. Serum microRNA-122-3p, microRNA-194-5p and microRNA-5099 are potential toxicological biomarkers for the hepatotoxicity induced by Airpotato yam. Toxicol Lett. 2017;280:125–32. · DOI
  146. Rissin D, Lopez-Longarela B, Pernagallo S. Poymerase-free measurement of microRNA-122 with single base specificity using single molecule arrays: detection of drug-induced liver injury. PLoS One. 2017;12(7):e0179669. · DOI
  147. Vliegenthart A, Berends C, Potter C, Kersaudy-Kerhoas M, Dear JW. microRNA-122 can be measured in capillary blood which facilitates point-of-care testing for drug-induced liver injury. Br J Clin Pharmacol. 2017;83(9):2027–33. · DOI
  148. Lee J, Ji SC, Kim B, Yi S, Shin KH, Cho JY, et al. Exploration of biomarkers for amoxicillin/clavulanate-induced liver injury: multi-omics approaches. Clin Transl Sci. 2017;10(3):163–71. · DOI
  149. Cho T, Uetrecht J. How reactive metabolites induce an immune response that sometimes leads to an idiosyncratic drug reaction. Chem Res Toxicol. 2017;30(1):295–314. · DOI
  150. Dakhoul L, Ghabril M, Chalasani N. Drug-induced chronic liver injury. J Hepatol. 2018;69(1):248–50. · DOI
  151. Stieger B, Mahdi Z. Review: model systems for studying the role of canalicular efflux transporters in drug-induced cholestatic liver disease. J Pharm Sci. 2017;106(9):2295–301. · DOI
  152. Ali I, Welch M, Lu Y, Swaan PW, Brouwer KL. Identification of novel MRP3 inhibitors based on computational models and validation using an in vitro membrane vesicle assay. Eur J Pharm Sci. 2017;103:52–9. · DOI
  153. Ogese M, Faulkner L, Jenkins R, French NS, Copple IM, Antoine DJ, et al. Characterization of drug-specific signaling between primary human hepatocytes and immune cells. Toxicol Sci. 2017;158(1):76–89. · DOI
  154. Goda K, Kobayashi A, Takahashi A. Evaluation of the potential risk of drugs to induce hepatotoxicity in human-relationships between hepatic steatosis observed in non-clinical toxicity study and hepatotoxicity in humans. Int J Mol Sci. 2017;18(4):810. · DOI
  155. McEuen K, Borlak J, Tong W, Chen M. Associations of drug lipophilicity and extent of metabolism with drug-induced liver injury. Int J Mol Sci. 2017;18(7):1335. · DOI
  156. Bilgic Y, Yilmaz C, Cagin YF, Atayan Y, Karadag N, Harputluoglu MM. Albendazole induced recurrent acute toxic hepatitis: a case report. Acta Gastroenterol Belg. 2017;80(2):309–11.
  157. Bergland Ellingsen S, Nordmo E, Tore Lappegard K. Recurrence and severe worsening of hepatotoxicity after reintroduction of atorvastatin in combination with ezetimibe. Clin Med Insights Case Rep. 2017;10:1179547617731375. · DOI
  158. Mukthinuthalapati PK, Fontana RJ, Vuppalanchi R, Chalasani N, Ghabril M. Celecoxib-induced liver injury: analysis of published case reports and cases reported to the Food and Drug Administration. J Clin Gastroenterol. 2017;52(2):114–22. · DOI
  159. Muñoz MA, Kulick CG, Kortepeter CM, Levin RL, Avigan MI. Liver injury associated with dimethyl fumarate in multiple sclerosis patients. Mult Scler. 2017;23(14):1947–9. · DOI
  160. Lévesque AM, Yang CD, Elchebly C, Doré M. Hepatotoxicity associated with iopamidol. Am J Health Syst Pharm. 2017;74(10):636–40. · DOI
  161. Ahmad J, Odin JA, Hayashi PH, Chalasani N, Fontana R, Barnhart H, et al. Identification and characterization of fenofibrate-induced liver injury. Dig Dis Sci. 2017;62(12):3596–604. · DOI
  162. Almeida J, Sola-Valls N, Pose E. Liver injury and glatiramer acetate, an uncommon association: case report and literature review. Ther Adv Neurol Disord. 2017;10(11):367–72. · DOI
  163. Sako A, Bae S, Gushima T, Motoshita J, Bekki S, Abiru S, et al. Drug-induced liver injury associated with mosapride citrate: a report of two cases. Int Med. 2017;56:41–5. · DOI
  164. Choudhary N, Bodh V, Chaudhari S. Norethisterone related drug induced liver injury: a series of 3 cases. J Clin Exp Hepatol. 2017;7(3):266–8. · DOI
  165. Verma N, Kumar P, Mitra S, Taneja S, Dhooria S, Das A, et al. Drug idiosyncrasy due to pirfenidone presenting as acute liver failure: case report and mini-review of the literature. Hepatol Commun. 2017;2(2):142–7. · DOI

Cited by

Sorted by citations

Metadata

Authors
Real, M., Barnhill, M. S., Higley, C., Rosenberg, J., & Lewis, J. H.
Venue
Drug Safety
Publisher
Springer Science and Business Media LLC
Published
2018-10-20
Volume
42
Issue
3
Pages
365-387
ISSN
  • 0114-5916
  • 1179-1942
DOI
10.1007/s40264-018-0743-2
Cited by
103
References
0
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review